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Objective: To describe a case of esophageal ulcer associated with the use of alendronate. Case Report: This is the fifth case ever
described in the literature according to our bibliographic review. In our patient, the association between the drug and the esophageal
lesions was masked by the presence of a hiatal hernia, potentially a cause of the esophageal lesion. The persistence of the lesions
despite high doses of anti-reflux therapy called attention to the possibility of the relationship. The esophageal lesion healed soon
after suspension of alendronate. Discussion: The authors present a review of the literature and point to the need for diagnostic
investigation, to suspend such a drug from patients who experience dyspeptic symptoms while using it.
Uniterms: Endoscopy. Alendronate. Esophageal ulcer.
INTRODUCTION
he first description of an association between
alendronate and esophageal ulcer was recently
reported by Maconi et al.1  Few other reports
emphasize this relationship. We present a case of a patient
using alendronate who developed an esophageal ulcer that,
despite anti-secretory therapy, only healed after removal
of the drug. The authors present a review of the literature,
and to our knowledge, this is the first report in the Brazilian
medical literature.
CASE REPORT
A 53 year old female was diagnosed with osteoporosis
during a clinical examination for a dental implant. Treatment
was initiated with alendronate (10 mg/day), calcium
carbonate and vitamins A and D supplementation.
One week later, the patient began to complain of
dysphagia and odynophagia, accompanied by pyrosis.
Empirical treatment was initiated for gastro-esophageal
reflux with ranitidine (150 mg every 12 hours),
domperidone (10 mg before meals), and antacid at the
patient’s discretion. There was no improvement in
symptoms, and after one week of treatment an endoscopy
was performed that revealed a hiatal hernia and an ulcer
in the distal esophagus (Fig. 1), associated with erosions
in the mid esophagus (Fig. 2).  Esophageal biopsies ruled
out the presence of neoplasm, and the lesions were
considered to be part of the spectrum of the gastro-
esophageal reflux disease. The medication was changed
to cisapride (10 mg, 4 times/day) and proton pump inhibitor
(pantoprazole, 40 mg/day). Despite correct use of
medication by the patient, and although there was
improvement in symptoms, dysphagia and pyrosis
persisted.
After one month, endoscopy to re-evaluate the lesion
showed the permanence of the ulcer, although
inflammatory reaction apparently had improved. It was
also noted that extensive erosions of the mid esophagus
were still present, with normal mucosa between the two
lesions (Fig. 3). Biopsies again were negative for neoplasm.
The medication was changed again, increasing the dose
of pantoprazole to 40 mg, 2 times/day, and was associated
with 1 g of sucralphate, 4 times/day.
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Two weeks later, the patient continued to complain
of symptoms. It was decided then to suspend medication
for osteoporosis (alendronate) and maintain the anti-
secretory measures. There was great improvement in the
first 48 hours, and a new digestive endoscopy performed
after two weeks of improvement in symptoms revealed
only the presence of the hiatal hernia, without ulcer or
other inflammatory abnormalities (Fig. 4). The anti-
secretory medication was gradually suspended and the
patient is currently off medication and asymptomatic.
DISCUSSION
Esophageal ulcers can appear as a consequence of
gastro-esophageal reflux, mainly in association with hiatal
hernias. Although not frequent, the appearance of these
ulcers identifies those with severe gastro-esophageal reflux.
The presence of hiatal hernia in the case described here
was, apparently, a confusing factor in the establishment of
a definitive diagnosis. Due to the hernia, the presence of
the esophageal ulcer was attributed to gastro-esophageal
reflux disease and not to the use of alendronate.
Sodium alendronate is a potent aminobiphosphonate
that inhibits bone reabsorption through the inhibition of
osteoclastic activity. Contrary to the first and second
generation biphosphonates (etidronate, chlodronate), that
were associated with pronounced and frequent adverse
effects (vomiting, diarrhea, dyspepsia), alendronate is
apparently much more tolerable.2 In addition, its effect on
the prevention of fractures due to osteoporosis has been
proven.3 Its use for the treatment of osteoporosis during
menopause has shown progressive increase in bone mass
and decreases in vertebral fracture incidence and height
loss over a period of three years.4
In 1996, Maconi et al.1 were the first to describe the
possible link between alendronate and esophageal ulcers. In
their report, a 59 year old patient had retrosternal pain,
odynophagia and dysphagia, some days after having initiated
therapy with alendronate, 5 mg/day. Endoscopy revealed
esophageal erosions and she was medicated with omeprazole.
After 8 weeks, endoscopy did not reveal any other
abnormalities. The authors emphasize the fact that the patient
was taking the alendronate pills with little water and while
lying in bed, from which one could suppose that the
esophageal lesion had been caused by direct contact of the
drug with the esophageal mucosa. In our case, this did not
seem to be an important factor, since the patient followed the
directions concerning the proper way to take the medication.
De Grown et al.4 described 3 cases of esophageal
lesion associated with the use of alendronate. In all of the
Figure 1 - First endoscopy picture. A small hiatal hernia is
seen, with large superficial ulceration.
Figure 2 - The endoscope is positioned in the mid esophagus
and superficial erosions can be seen.
patients, the lesion was extensive and severe, and the
esophageal lesions, as well as the symptoms, only
improved after suspension of alendronate, in spite of high
doses of anti-secretory drugs. In one of the cases reported,
esophageal lesions were severe enough to cause
hematemesis and stenosis. In addition to the description
of the three cases, the authors present a review of 5000
medicated patients, with 1213 patients reporting side
effects. Among such effects, 199 involved the esophagus,
and they were considered serious in 52 patients (26%).
The lesions were distributed equally between the middle
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and distal esophagus, and in some cases, the entire organ.
The symptoms appeared precociously, in the first month
after the initiation of the alendronate, and most patients
did not have any history of gastrointestinal disease.
The physiopathology of the esophageal lesions caused
by alendronate is still unknown. The hypothesis that the
drug causes lesions through direct contact with the mucosa
seems to be quite reasonable. Some of the patients with
lesions refer to the ingestion of the medication with an
amount of water less than that recommended, or even in a
supine position, making the passage of the capsule through
the esophagus difficult. In addition, the presence of hiatal
hernia and gastro-esophageal reflux could favor the reflux
of the drug even after the pill reaches the stomach.4
In any event, while such a mechanism remains
unclarified, patients who need to use the medication must
be oriented to take the pills with at least 1 glass of water,
and not lay down for at least one hour. This could minimize
the effects of drug contact with the esophageal mucosa.
Furthermore, the appearance of symptoms that suggest
esophageal lesions (dysphagia, odynophagia, pyrosis) must
be investigated immediately with upper digestive endoscopy
to evaluate the degree of the lesion. The suspension of
medication is fundamental to the healing of serious lesions.
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Figure 4 - After the patient had stopped alendronate, upper
endoscopy showed a hiatal hernia without any ulceration.
Figure 3 - An esophageal ulcer in the esophago-gastric
transition can be seen in this retroflexed (U-turn) view.
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RESUMO
Objetivo: Descrever um caso de úlcera esofágica associada ao uso de alendronato. Relato de caso: Este, segundo nossa
pesquisa bibliográfica, é o quinto caso descrito na literatura. Em nossa paciente, a associação entre a droga e a lesão esofágica
foi mascarada pela presença de hérnia de hiato, potencialmente causadora de lesão de esôfago. A persistência da lesão apesar
de doses elevadas de medicação anti-refluxo gastro-esofágica alertou para a possível associação. A lesão esofágica cicatrizou
logo após a retirada do alendronato. Discussão: Os autores fazem uma revisão da literatura e alertam para a necessidade de
investigação diagnóstica e retirada da droga, em pacientes em uso de alendronato e que desenvolvem queixas dispépticas.
